The cytoplasmic Rho family of GTPases plays a critical role in regulating actin microfilament dynamics. The control of cell shape and cell migration by Rho GTPases has attracted intense interest from the fields of cancer biology and cardiovascular medicine. More recently, it has become clear that Rho family proteins and their intracellular effectors participate in a range of neuronal functions from axonal growth to neuronal differentiation to neuronal survival to regeneration.
Rho-GTPases
By sequence homology, the Ras-superfamily of GTPases can be subdivided into 9 families: Ras, Rab, Arf, Ran, Rad, Rheb, Rag, Rit and Rho (Blumenstein 2004) . Clustal W algorithm alignment of the RhoGTPase domains allowed the 22 mammalian RhoGTPases to be grouped into eight subclasses (Aspenstrom and others 2004) . A revised classification employing Clustal X neighborjoining combined with ProML maximum likelihood methods indicated that two out of these 22 Rho GTPases⎯ Miro-1 and Miro-2, or Wrch-1 and Wrch-2⎯are best considered an autonomous Ras-like family (Boureux and others 2007) . Hence, 20 mammalian RhoGTPases constitute eight subclasses, fulfilling tasks that include cell growth and transformation control (Zohn and others 1998) , actin filament (re)organization in fibroblasts (Voncken and others 1995; Zohn and others 1998; Johnson 1999; Cerione 2004; Jaffe and Hall 2005; Vardouli and others 2005) , mitogen-activated protein kinase cascade activation, G1-S cell cycle regulation, gene transcription (Zohn and others 1998; Olofsson 1999; Narumiya and others 2004) , cytokinesis regulation, microtubule dynamics, cell adhesion, endo-and exocytosis, migration, and survival (Van Aelst and D'Souza-Schorey 1997; Etienne-Manneville and Hall 2002; Cerione 2004 ).
An overview of the eight subclasses of RhoGTPases are shown in Table 1 , together with their common expression patterns (Wennerberg and Der 2004; Ridley 2006) and effects on the actin filament system after transfection into porcine aortic endothelial cells (Aspenstrom and others 2004) . For a recent SAGE analysis of the mRNA expression of 17 RhoGTPases in mouse tissue, refer to Boureux and others (2007) .
The general structure of RhoGTPases, as shown in Figure 1A , consists of several core components. An effector domain is made accessible by guanosine triphosphate (GTP)-induced conformational changes in two "switch" domains between residues 28-44 and 62-69 of RhoA (Hakoshima and others 2003) . The hypervariable region differs not only between the RhoGTPase subclasses but also between the isoforms within one subclass in terms of the presence of a polybasic region or a palmitoylation site (Ridley 2006 geranylgeranyltransferase type 1. In Rho family proteins where X = serine, methionine, glutamine, or alanine, prenylation is catalyzed by protein farnesyl transferase to add a farnesyl group. As predicted by its sequence, RhoA is modified by a thioether linkage of C20 geranylgeranyl to the COOH-terminal cysteine residue ( Fig. 1B ) (Katayama and others 1991) . Protein prenylation is known to be required for membrane targeting and function (Lane and Beese 2006; Leung and others 2006) . Prenylated RhoA initially associates with the membrane of the endoplasmic reticulum (ER), where proteolysis, catalyzed by the CAAX protease Ras and α-factor-converting enzyme (Rce1), occurs immediately C-terminal to the geranylgeranylated cysteine ( Fig. 1B ) (Lane and Beese 2006) . The carboxyl-terminal geranylgeranylcysteine of RhoA can be methylated at its alpha-carboxy-residue by the ER-membrane bound protein-S-isoprenylcysteine O-methyltransferase (systematic name, S-adenosyl-L-methionine: protein-Cterminal-S-farnesyl-L-cysteine O-methyltransferase)⎯an enzyme with a high activity for C-terminal S-farnesyl-Lcysteine and lower affinities for C-terminal S-geranylgeranyl-L-cysteine and S-geranyl-L-cysteine (Stephenson and Clarke 1990; Volker and others 1991; Perez-Sala and others 1992) . This reversible process of methylation (see Fig. 1C ) is thought to facilitate membrane attachment and interactions with effector proteins, as described for other proteins (Hancock and others 1991; Silvius and l'Heureux 1994; Parish and others 1995) and for RhoGTPases (Lane and Beese 2006) . Amino terminal to the CAAX box there is another region thought to contribute to proper subcellular targeting (not shown in Fig. 1 ). This region contains either a series of basic amino acids or cysteine residues acting as palmitoylation sites (Hancock and others 1990; Michaelson and others 2001) .
ROCKs (Structure, Regulators, and Localization)
The first identified and most exhaustively studied downstream targets of RhoA are the Rho-associated coiled-coilcontaining protein kinases (also known as ROCKs) (Leung and others 1995; Fujisawa and others 1996; Leung and others 1996; Matsui and others 1996; Nakagawa and others 1996) . There are two genes encoding two protein isoforms: ROKα (Leung and others 1996) (also termed ROCKII [Matsui and others 1996; Nakagawa and others 1996] or Rho kinase [Matsui and others 1996] ) and ROKβ (Leung and others 1995) (also referred to as ROCKI or p160ROCK [Palmer and others 1994]). The ROCKs are two of the more than 50 members of the ACG kinase family (Proud 2007 ). The ROCK serine/threonine kinases consist of three major domains: a RhoA binding domain (RBD) situated in a coiled-coil region (CCR), a kinase domain that is responsible for its catalytic activity and a cysteine-rich domain encompassing pleckstrin-homology domain that is thought to participate in protein localization . Both ROCK isoforms are activated by RhoA binding to the RBD (Leung and others 1995; Fujisawa and others 1996) . Intracellular second messengers such as arachidonic acid and sphingosylphosphorylcholine also have activating effects on ROCKs (Fu and others 1998; Shirao and others 2002) . Furthermore, the autoinhibitory C-terminus of ROCKI can be cleaved proteolytically by caspase 3, a process occurring during apoptosis and leading to increased ROCKI activity (Coleman and others 2001; Sebbagh and others 2001) . Inhibitors for ROCKI include Gem, which is thought to change the substrate specificity by binding to the CCR (Ward and others 2002) , and RhoE/Rnd3, which acts as an inhibitor by binding to the kinase domain (Riento and others 2003) . In the case of ROCKII, Rad serves as an inhibitor by binding to the CCR of the protein (Ward and others 2002). The structure and regulation of ROCKI and ROCKII are summarized in Figure 2 . Although the two ROCK isoforms share 65% identity in their amino-acid sequences, the highest similarities are found in their kinase domains, which are 92% identical (Nakagawa and others 1996) . ROCK autophosphorylation implies that autoregulation contributes a physiological function for these kinases. The ROCKs also phosphorylate a range of effector proteins (Ishizaki and others 1996; Leung and others 1995) . Downstream targets that can be phosphorylated by ROCK include the consensus amino acid sequences R/KXS/T or R/KXXS/T (R, arginine; K, lysine; S, serine; T, threonine; X, any amino acid) Sumi and others 2001) . As shown in Figure 3 , the α-helical RBD assembles into a parallel coiled-coil in ROCKI (Dvorsky and others 2004) and ROCKII (Chen and others 2002; Shimizu and others 2003) . Even though differences in the spatial arrangement of the coiled-coil do occur between the two isoforms, the Cterminal structures of the RBD are highly similar. The minimal RhoA-interacting motif (residues 998-1010 of ROCKI), located in the C-terminal part of the ROCK-RBD, is identical in ROCKs of different organisms (Dvorsky and others 2004) . The structure of the ROCKI/RBD interaction is illustrated in Figure 3 .
Even though the ROCK isoforms share the structural similarities mentioned above, their localization in the body differs. The ROCKII mRNA is preferentially found in brain and heart tissue, whereas ROCKI mRNA is predominant in other tissues (Leung and others 1996; Nakagawa and others 1996; Di Cunto and others 2000; Wei and others 2001; . Pyramidal neurons of the hippocampus and cerebral cortex and Purkinje cells of the cerebellum are the cells with the highest ROCKII expression (Hashimoto and others 1999) . By immuno-fluorescence and cell fractionation, ROCKII was found to be primarily cytoplasmic and a minor fraction is associated with cellular membranes (Leung and others 1995; Matsui and others 1996; Kimura and others 1998) . A subset of ROCKII colocalizes with actin stress fibers (Katoh and others 2001; Chen and others 2002) , and with the vimentin intermediate-filament network in serum-starved cells (Sin and others 1998) . A portion of ROCKI is reported to colocalize with centrosomes (Chevrier and others 2002) .
ROCK-Effectors and Cytoskeleton
A variety of effectors for ROCKs have been described ( Fig. 4 ). Downstream targets include phosphatidylinositol-3-kinase/protein kinase akt (leading to decreased activation of the endothelial nitric oxide synthase) (Ming and others 2002; Wolfrum and others 2004), the insulin receptor substrate-1 (resulting in uncoupling of insulin receptor from phosphatidylinositol-3-kinase and potentially GLUT4 activation) (Farah and others 1998) , and various cytoskeletonorganization regulating proteins (discussed in detail below).
One intensively studied downstream target of ROCKs is the myosin-II regulatory light chain phosphatase (MLCP), an enzyme consisting of a 20kDa noncatalytic subunit (M21), a 37kDa catalytic subunit (PP1δ), and a 110-130kDa targeting domain, termed the myosin binding site between human ROCKI-RBDs (residues 947-1015; labeled green and brown) and the truncated forms of human RhoA (residues 1-181; labeled magenta and cyan) bound to the nonhydrolyzable GTP analogue Gpp (NH)p (stabilized by Mg 2 ). A-D, Display of the complex of two RhoA molecules and two ROCKI molecules from different angles. The close up in B shows the area of ROCKI-RBD/RhoA interaction. The same perspective, only turned 180 degrees around the helix-axis, is employed in E and F, where the residues of ROCKI-RBD, interacting with RhoA, are labeled yellow. These residues include K999, V1003, N1004, L1006, A1007, and M1010 in the brown-labeled α-helix and L998, Q1001, A1002, and K1005 in the green-labeled α-helix. Whereas A-D are rendered in "worms-style," E uses the "space-fill-style" and F the "ball-and-stick-style."
(MBS) or myosin phosphatase targeting peptide. After phosphorylation of the MBS at threonine 697 and threonine 855 by ROCKII , the enzyme activity of MLCP is decreased via inhibition of MBS's ability to activate the PP1δ, resulting in less dephosphorylation and thus lower inactivation of myosin-II regulatory light chain (MLC) (Noda and others 1995; Kimura and others 1996; Hartshorne and others 1998; Somlyo and Somlyo 2000) . Increased cellular contractility and stress fiber formation are the main effects of this signaling due to induced interaction of MLC with actin. The net effect is an activation of the myosin ATPase (Zhao and Manser 2005) . ROCKII is also able to phosphorylate MLC at serine 19, a phosphorylation site shared with MLC kinase, to shift MLC into the active form. ROCK-mediated phosphorylation of threonine 38 in the 17 kDa protein kinase Cpotentiated inhibitor (CPI-17) potentiates this protein's inhibitory action on MLCP (Somlyo and Somlyo 2000) . Additionally, RhoA can bind to the C-terminal site of the MBS (Kimura and others 1996; Hartshorne and others 1998), providing a parallel ROCK-independent mechanism to regulate cellular contractility (for clarity, not shown in Fig. 4 ).
LIM-domain (Lin11, Isl1, Mec3)-containing protein kinases 1 and 2 (LIMK1/2) are phosphorylated by ROCKI at threonine 508 and threonine 505, respectively, enabling these enzymes to phosphorylate and thus inactivate cofilin at serine 3. The reduced binding to F-actin by phosphorylated cofilin/actin depolymerizing factor attenuates its ability to catalyze F-actin depolymerization and severing (Maekawa and others 1999; Stanyon and Bernard 1999; Ohashi and others 2000; Sumi and others 2001) .
Another ROCKII effector is α-Adducin, a membrane skeletal protein that binds to spectrin and promotes the association of that molecule with F-actin (Kimura and others 1998; Fukata and others 1999) . Thought to play its role in spectrin-actin network assembly by capping of actin and by spectrin recruitment to the growing ends of actin filaments, α-Adducin shows enhanced binding activity to F-actin after phosphorylation by ROCKI. This has been shown to occur preferentially beneath to the plasma membrane at ruffles .
Cross-linking of membrane proteins and actin filaments near the cell surface is promoted by head-to-tail association of ezrin, radixin, and moesin (ERM) proteins. The ERM proteins are additional substrates of the ROCKs. Following the phosphorylation of the ERM proteins at threonine 567, threonine 564, and threonine 558, respectively, cross-linking of actin filaments is disrupted, permitting cytoskeletal reorganization (Matsui and others 1998) .
Activated by ROCKI, the Na + /H + -exchanger-1 functions in RhoA-induced reorganization of actin filaments (Denker and others 2000; Tominaga and Barber 1998) and also as an ERM-binding protein and ion exchanger, contributing to fibroblast migration (Tominaga and Barber 1998; Denker and Barber 2002) .
Intermediate filament proteins such as vimentin, glial fibrillary acidic protein (GFAP), and neurofilament protein (NF-L) are phosphorylated by ROCKII at multiple residues. In vitro, vimentin filament disassembly and impaired GFAP-or NF-L filament formation have been reported after phosphorylation by ROCKII (Kosako and others 1997; Goto and others 1998; Hashimoto and others 1998) .
Other downstream targets of ROCKII include F-actin binding proteins such as eukaryotic elongation factor 1α (EF-1α), myristylated alanine-rich C kinase substrate (MARCKS), and calponin. For these proteins, phosphorylation leads to decreased actin binding activity (Winder and Walsh 1990; Izawa and others 2000; Nagumo and others 2001) .
RhoA-Effectors and Cytoskeleton
Activated RhoA does not signal through ROCK alone, although in many systems, ROCK is essential for signal transduction. Other effectors include mammalian diaphanous (mDia) and citron kinase (CitK). mDia possesses an actin-nucleating region (FH2 domain) and is able to nucleate parallel, unbranched actin filaments after binding of RhoA to the protein's N-terminus, a process that results in unfolding and thus activation of the nucleating activity (Ridley 2006) . CitK is suggested to be involved in the formation of the contractile ring, consequently playing a role in cytokinesis, possibly by participation in regulating di-phosphorylation of MLC (Goto and others 2000; Yamashiro and others 2003) .
ROCKs in the CNS
As stated above, certain intermediate filament proteins are regulated by ROCKII. Belonging to the type IV family of intermediate filaments, NF-L is found in high concentrations along axons of vertebrate neurons. NF-L undergoes depolymerization after phosphorylation by ROCKII (Kosako and others 1997; Goto and others 1998; Hashimoto and others 1998 ). An increase in NF-L is reported to result in a higher number of filaments and decreased interfilament distance. The intriguing hypothesis that ROCKII/neurofilament interactions have an effect on axonal diameter remains to be tested.
Microtubule-associated proteins (MAPs), such as Tau or MAP2, play major roles in shaping neuronal morphology by altering microtubule dynamics (Hirokawa 1994; Mandelkow and Mandelkow 1995) . Tau and MAP2 can be phosphorylated by ROCKII to decrease microtubule polymerization (Amano and others 2003) . Suppression of microtubule and neurofilament assembly is seen after RhoA/ROCKII activation in neuroblastoma cells Hirose and others 1998; Katoh and others 1998) , consistent with Tau and MAP2 participating in neurite retraction.
Collapsin response mediator protein 2 (CRMP2), a neuronal protein that is associated with semaphorin-3A and lysophosphatidic acid-induced growth cone collapse and axon outgrowth (Goshima and others 1995; Arimura and others 2000; Inagaki and others 2001) , is another ROCKII effector. The axon guidance functions that are associated with ROCKII/CRMP2 signaling illustrate a role for ROCKs during the development of the central nervous system. As much as a lipid-kinase-mutant form of PtdIns(4)P5K inhibits ROCK-induced growth cone collapse, the native form might also function downstream of ROCKII-induced neurite retraction (Yamazaki and others 2002) . Actin-myosin-interaction regulating proteins like LIMK1/2 and MLC (Fig. 4) To evaluate the in vivo functions of CNS ROCKs, inhibitors have been administered in several model systems. Beneficial neurological effects were observed in animal models of Alzheimer's disease, neuropathic pain, demyelinating/inflammatory diseases (eg, multiple sclerosis), stroke, and in spinal-cord injuries (reviewed in Mueller and others 2005) . As a caveat, it must be appreciated that the ROCK small molecule inhibitors do not distinguish between ROCKI and ROCKII. Moreover, the close relationship of ROCKs to other ACG kinases leaves open the possibility that some of these effects are mediated by other kinases. Thus, many of these pharmacological experiments should be confirmed by genetically specific RNAi or knock-out animal models.
Rho-GTPase Regulators
Over the past 30 years, a growing interest for small GTP-binding proteins (GTPases) and their influence on cell morphogenesis has developed. Regarded as important molecular switches for the developing and reorganizing cytoskeleton, Rho family GTPases were soon found to play a key role in neuronal morphogenesis. As mentioned above, the Rho family GTPases comprise a set of related proteins⎯more than 20 have been identified in humans, and at least 7 of them play a role in dendrite development (Negishi and Katoh 2005) . For clarity, we focus here primarily on RhoA⎯one of the most important GTPases for modulation of cell morphology and motility in neurons. After examining the downstream effects of RhoA, the question of how this molecular switch is regulated shall be addressed.
As illustrated in Figure 5 , Rho GTPases are inactive when bound to guanosine diphosphate (GDP) but change into their active conformation after binding to GTP. Their activity in mammalian cells is known to be regulated by a family of at least 85 guanine nucleotide exchange factors (GEFs), 80 GTPase-activating proteins (GAPs), and three guanine nucleotide dissociation inhibitors (GDIs) (Jaffe and Hall 2005) . GEFs are activators for downstream signaling⎯they turn on the switch by catalyzing the exchange of GTP for GDP (Schmidt and Hall 2002) . On the other hand, GAPs inhibit downstream signaling by stimulation of the intrinsic GTPase activity leading to hydrolysis of GTP to GDP (Bernards 2003; Moon and Zheng 2003) . In resting cells, Rho GDIs form a complex with Rho GTPases protecting them from GDP-release and⎯by shielding their isoprenylated hydrophobic tails from aqueous solvent⎯prevent them from membrane association (Olofsson 1999) .
RhoA GDIs
Unlike GEFs and GAPs, there are only a few GDIs known to regulate Rho GTPases: RhoGDI-1 (α), RhoGDI-2 (D4/LyGDI/β), and RhoGDI-3 (γ). In addition, there are several sequence-unrelated proteins that may exert GDI activity for Rho GTPases (Anastasiadis and others 2000) . RhoGDI-1 is the most extensively studied GDI and is known to function as a GDI for RhoA, Cdc42, and Rac1. With an intracellular concentration equal to that of the GTPases themselves (Michaelson and others 2001), RhoGDI-1 is able to regulate RhoA, Cdc42, or Rac1 stoichiometrically. RhoGDI-3 has its highest affinity toward RhoB and RhoG, with reduced binding affinity for RhoA and Cdc42 (Adra and others 1997). RhoGDI-2 binds only very weakly to RhoA (Olofsson 1999) , and thus is not thought to play a major role in RhoA regulation.
With its high expression level, RhoGDI-1's binding to RhoA needs to be regulated⎯a function that is carried out by various modulators including Protein kinase A, which stabilizes the complex through phosphorylation of a Cterminal serine residue in RhoA (Lang and others 1996) . A recently discovered Src-mediated phosphorylation of Tyr156 decreases the level of RhoA/RhoGDI-1 complex drastically and thereby presents another regulatory mechanism for Rho GTPase activity (DerMardirossian and others 2006) .
In addition to regulating the activity levels of Rho GTPases, RhoGDI-1 is essential for their subcellular localization. Instead of targeting to cell membranes like the closely related RhoB, RhoA is largely cytosolic (Michaelson and others 2001) . This difference in localization is attributable to the differences in RhoGDI binding. The C-terminal CAAX sequence of Rho GTPases is the site of different posttranslational modifications, including isoprenylation of the highly conserved cysteine residue (Hakoshima and others 2003) . Through this hydrophobic tail, Rho GTPases are able to anchor in membranes. RhoGDIs target this anchor and sequester Rho proteins in the cytosol by folding into an immunoglobulin-like βsandwich capable of capturing the geranylgeranyl chain of 
RhoA GEFs and GAPs
Many distinct GEFs and GAPs regulate RhoGTPase activity in the cell. Concerning RhoA, one may distinguish between GEFs/GAPs that are being activated through direct or indirect downstream effects of various ligand/ receptor systems at the cell surface. To illustrate the diversity of signaling mechanisms, this review concentrates on a selected group of receptors regulating neuronal RhoA-GTPases: EphA-, ApoER2-, NgR-, amino-NogoR-, PlexinB1-, LPA 1 -, and Robo-receptors (Fig. 6) .
RhoA Activation by Receptor Tyrosine Kinase Signaling
Several receptor tyrosine kinases (RTKs) have been shown to regulate Rho GTPase activity (Table 2) . Eph receptors are prominent among RTKs in their influence on RhoA-signaling. After binding of their ephrinligands, Eph receptors become activated by formation of higher-order signaling clusters (Himanen and others 2001; Wimmer-Kleikamp and others 2004) . They participate in the regulation of attraction/repulsion, adhesion/ de-adhesion, and migration and thereby directly regulate cell fate, morphogenesis, and organogenesis during development and neuronal plasticity such as dendritic spine formation during adulthood (Klein 2004) . Anchored in the plasma membrane with its transmembrane domain, an Eph receptor possesses an extracellular ligand binding domain that recognizes ephrin stimuli and an intracellular catalytic domain that transmits these signals into the cell. The extracellular domain is composed of a globular domain (ephrin-binding region), a cysteine-rich region, and Fibronectin-type III repeats. The intracellular region contains a juxtamembrane domain, a kinase domain, a SAM domain, and a PDZ-binding motif.
With overlapping expression patterns and multiple binding partners, Eph receptors' functions are often redundant (Klein 2004) . Based on sequence homologies and the membrane anchoring of ligands, these proteins are grouped as EphA receptors (type 1-8 in mammals), EphB receptors (type 1-4 and 6), ephrinA GPI-anchored ligands (type 1-5), and ephrinB transmembrane ligands (type 1-3). Whereas EphAs bind to most or all ephrinAs, EphBs bind to most or all ephrinBs. The only known exceptions to this rule are EphA4 and ephrinA5. EphA4 binds to ephrinAs and ephrinBs (Kullander and Klein 2002) , and ephrinA5 binds not only to EphAs but also to EphB2 (Himanen and others 2004; Pasquale 2004) . Ephrin-Eph interactions may lead to forward signaling into the Ephexpressing cell but can also lead to reverse signaling into the ephrin-expressing cell, or bi-directional signaling into both cells (Klein 2004) .
Forward signaling in the Eph/ephrin pathway proceeds by one of two pathways, a direct interaction with certain GEFs such as Ephexin (see below) (Shamah and others 2001) or the initiation of a phosphorylation cascade. The first step in this cascade is the interdigitation of the fibronectin type III repeats and SAM domains of the receptors with the ligands' amino-terminal domains to cluster a signaling complex (Lackmann and others 1998; Stapleton and others 1999; Thanos and others 1999) . The receptors' PDZ domain proteins also contribute to clustering (Himanen and others 2001) . Aggregation leads to autophosphorylation of the Eph receptors on several cytoplasmic tyrosine residues (Kalo and Pasquale 1999) . Initial phosphorylation disrupts inhibitory interactions between receptor juxtamembrane and kinase domain, begetting further activation of kinase activity and an open SH2-domain binding site (Binns and others 2000; Zisch and others 2000; Wybenga-Groot and others 2001). The latter then interacts with downstream signaling molecules.
The GEFs Ephexin and Vms-Rho activate RhoA downstream of EphA receptors, whereas EphB receptors signal to Rac and Cdc42 through Kalirin and Intersectin. As an EphA-GEF in neurons, Ephexin activates primarily RhoA, and to a lesser extent Cdc42 (Rodrigues and others 2000; Shamah and others 2001). Ephexin's tandem Dbl homology domain (DH) and pleckstrin homology domain (PH) are required for the catalytic activity of Dbl family exchange factors; the amino-terminal hydrophobic region may promote membrane localization. Ephexin also contains an SH3 domain and an acidic box (Noren and Pasquale 2004) . Vms-RhoGEF is closely related to ephexin by sequence and mechanisms of action but is expressed principally in EphA4-positive vascular smooth muscle cells (Shamah and others 2001; Ogita and others 2003) . Vms-RhoGEF interacts with EphA4 to assemble actin stress fibers and to regulate vascular contractility. Little is known about the mechanisms by which EphA receptors activate these two GEFs. However, it has been shown that ephrin-A1/EphA4 binding leads to phosphorylation of Vms-RhoGEF tyrosine residues (Ogita and others 2003) , suggesting a regulation by tyrosine phosphorylation (Noren and Pasquale 2004) . Since Ephexin is a member GEF = guanine nucleotide exchange factor; Vsm = vascular smooth muscle; Larg = leukemia-associated Rho guanine; INSR = insulin receptor; IGF1R = insulin-like growth factor-1 receptor; PDGFR = platelet-derived growth factor receptor; EGFR = epidermal growth factor receptor; αPix = PAK-interacting exchange factor alpha; βPix = PAK-interacting exchange factor beta; Sos = son-of-sevenless; P-Rex = phosphatidylinositol (3,4,5)-trisphosphate-dependent Rac exchanger; RET = REarranged during transfection; MET = met proto-oncogene (hepatocyte growth factor receptor); TIE = tyrosine kinase with Ig and EGF homology domains; VEGFR = vascular endothelial growth factor receptor.
of a family of five GEFs (Ephexin, Vms-RhoGEF, TIM/ Arhgef5, Neuroblastoma, SGEF/FLJ12822), similar signaling mechanisms and functions in its close relatives are suspected. Future studies employing knockout models for these GEFs and EphAs might be helpful to answer these questions.
RhoA Activation by G-Protein Coupled Receptor-Signaling
The seven transmembrane domain G-protein coupled receptors (GPCRs) are the most common receptor type in mammalian proteomes and are known to activate Gproteins that regulate a variety of downstream effector pathways, including the RhoA signaling pathway. After binding its ligand, a GPCR promotes the exchange of GDP for GTP on a coupled heterotrimeric G α subunit within the cell. When GTP is bound, G α is in an activated state that dissociates from the G βγ subunit. One or both subunits then regulate specific downstream effectors such as adenylate cyclases, phospholipases, or ion channels. In the case of RhoA signaling, relevant GPCRs couple to heterotrimeric G 12 / G 13 and then link to several RhoGEFs such as LARG, PDZ-RhoGEF, or p115-RhoGEF (Vogt and others 2003) . These RhoGEFs are able to associate with G 12 / G 13 via their N-terminal "regulators of G-protein signaling" (RGS) domains (Fukuhara and others 1999; Fukuhara and others 2000) . One GPCR influencing RhoA activity is the LPA 1 receptor. Its ligand, lysophosphatidic acid, induces neurite retraction and activates RhoA (Jalink and others 1993; Jalink and others 1994; Tigyi and others 1996; Kranenburg and others 1999) . Inhibition of RhoA or ROCK blocks LPA-induced growth cone collapse. Interestingly, receptor tyrosine kinase inhibitors were also shown to decrease the LPA-induced retraction effect, leading to the conclusion that tyrosine kinases as well as ROCKs must be involved in the signaling cascade (Sayas and others 2006) . Pyk2 is a Ca 2+ -sensitive tyrosine kinase known to phosphorylate/ activate glycogen synthase kinase-3 (GSK-3), which acts as a multifunctional serine/threonine kinase to target microtubule-binding proteins, promoting microtubule destabilization and neurite retraction. LPA 1 receptors couple through G 12 / G 13 to activate RhoA and also couple through Gi/Gq to phospholipase C activation, Ca 2+ mobilization, and Pyk2 (Sayas and others 2006) . Thus, parallel pathways ensure robust neurite retraction.
RhoA Activation by Plexin Receptor-Signaling
Plexins are transmembrane proteins that in the nervous system mediate the axon repellant actions of semaphorins. Human plexins comprise 4 major subfamilies: plexin-A-D (Tamagnone and others 1999) . In general, membrane-associated semaphorins directly activate plexins. In contrast, most secreted semaphorins bind with highest affinity to neuropilins (Takahashi and others 1999) . Subsequently, neuropilins complex with plexinAs to transmit signals to the cytosol Takahashi and others 1999; Waimey and Cheng 2006) .
Through their PDZ-interacting C termini, plexin-Bs, but not other plexins, were shown to associate with PDZ-RhoGEF and LARG (Swiercz and others 2002) . Semaphorin 4D activation of plexin-B1 was found to activate PDZ-RhoGEF and LARG leading to RhoA activation and downstream signaling (Aurandt and others 2002; Perrot and others 2002; Swiercz and others 2002) . For other plexins, there is evidence that coupling to Rho family GTPases occurs by direct protein/protein interactions without an intervening GEF or GAP protein (Oinuma and others 2004) .
RhoA Activation by Nogo Receptor-Signaling
In the adult CNS, axonal growth is limited and myelin proteins play a role in inhibiting axonal extension. Within the neuron, axonal RhoA plays a role in mediating this inhibition. Three proteins in CNS myelin, Nogo-A, Myelinassociated glycoprotein (MAG), and oligodendrocytemyelin glycoprotein (OMgp), are recognized as ligands for axonal receptors mediating outgrowth inhibition (McGee and Strittmatter 2003; Liu and others 2006) . The axonal Nogo-66 receptor (NgR) was identified based on its ability to bind a fragment of Nogo-A (Fournier and others 2001; Hunt and others 2002) . However, NgR also binds MAG (Domeniconi and others 2002; Liu and others 2002) and OMgp (Wang, Koprivica, and others 2002) . Although Nogo, MAG, and OMgp do not show sequence homologies, these three proteins do compete for NgR binding (Domeniconi and others 2002; Wang, Koprivica, and others 2002) , suggesting similar signaling through the same active site by using different but overlapping binding sites at Nogo receptor.
NgR is a glycosylphosphatidylinositol (GPI)-anchored membrane protein, so a transmembrane protein is thought to mediate communication to the cell interior (Fournier and others 2001) . At least in some cells, the low-affinity neurotrophin receptor p75NTR serves as a signal transducing co-receptor (Wang, Kim, and others 2002) . Another transmembrane protein, LINGO-1, is reported to facilitate the coupling of p75NTR to NgR (Wang, Kim, and others 2002; Wong and others 2002; Mi and others 2004) , and TAJ/TROY (an orphan member of the tumor necrosis factor receptor family) may substitute for p75NTR as a co-receptor (Park and others 2005; Shao and others 2005) . Several studies have confirmed that a NgR complex activates RhoA to inhibit axonal growth (Jin and Strittmatter 1997; Lehmann and others 1999; Borisoff and others 2003; Fournier and others 2003) , but how the complex is coupled to RhoA is less clear. One report suggests that ligand binding to NgR suppresses a RhoGDI activity within the intracellular domain of p75NTR (Yamashita and Tohyama 2003) .
RhoA Activation by Lipoprotein Receptor-Signaling
ApoER2 was identified as an LDL receptor-related gene (Takahashi and others 1992; Kim and others 1996; Novak and others 1996; Herz 2001) . Although ApoER2 was initially thought to play a role in lipid metabolism, it was soon found to be expressed solely in neural and testicular tissues (Stockinger and others 1998; Stockinger and others 2000) . Double knockout mice for ApoER2 and another LDL receptor family gene, VLDL , develop profound ataxia secondary to cerebellar dysplasia. Defects of neuronal cell positioning in the forebrain resembled those in the reelin knockout mouse, "reeler," and the Dab1 (Disabled-1) knockout mouse, "scrambler" (Falconer 1951; Sweet and others 1996) . This observation led to the suggestion that ApoER2 and VLDL receptors might function as reelin receptors coupled to Dab-1 intracellularly. Binding assays of reelin with the two receptors' extracellular domains supported this hypothesis (D'Arcangelo and others 1999; Hiesberger and others 1999). Dab1 was found to interact with the cytoplasmic NPxY motif of ApoER2 and VLDL receptors, and extracellular reelin binding led to tyrosine phosphorylation of Dab1 (D'Arcangelo and others 1999; Hiesberger and others 1999; Trommsdorff and others 1999; Hoe and others 2006) .
Reelin/ApoER2/Dab-1 signaling to control cell positioning and cell survival occurs through several mechanisms (May and others 2005) . Important for the coupling to RhoA activation is the binding of the c-Jun N-terminal kinase (JNK) interacting proteins 1 and 2 (Jip1/2) to an alternatively spliced, ApoER2-specific insert (May and others 2005) . Jip1/2 assembles components of a MAP kinase signaling module (Yasuda and others 1999) and is thought to bind RhoGEF, which then activates RhoA (Meyer and others 1999) . The interaction of JIP-1 with RhoGEF was confirmed by coimmunoprecipitation of these proteins from lysates of transiently transfected HEK 293 cells (Meyer and others 1999) .
RhoA Deactivation by Roundabout (Robo) Receptor-Signaling
Roundabout proteins function as Slit receptors. Their role in midline axonal guidance is evolutionarily conserved from C elegans and Drosophila (Kidd and others 1998; Zallen and others 1998) to mouse (Taguchi and others 1996; Brose and others 1999; Yuan and others 1999) and humans (Kidd and others 1998) . Transmembrane Robo proteins are composed of five immunoglobulin (Ig) domains, three extracellular fibronectin III repeats, and a large intracellular region that contains several conserved CC motifs (Kidd and others 1998; Zallen and others 1998) . The Robo Ig domains bind to the leucine-rich repeat (LRR) domains of Slits (Howitt and others 2004) , and the intracellular motifs are responsible for Robo-specific responses (Bashaw and Goodman 1999; Bashaw and others 2000) . Robo/Slit signaling can direct both axon repulsion (Seeger and others 1993; Kidd and others 1998; Zallen and others 1998; Brose and others 1999; Challa and others 2001; Lee and others 2001) and neuronal migration (Wu and others 1999; Zhu and others 1999) . Signaling by the SAX-3/Robo receptor of C elegans requires a complex of the juxtamembrane and CC1 region with the VAB-1 tyrosine kinase (Ghenea and others 2005) .
Ligand binding to Robo receptors suppresses the level of the GTP-bound form of a Rho family GTPase, Cdc42. This action is mediated via slit-robo-GAP (srGAP) proteins, which contain an SH3 domain that binds to the CC3 motif in Robo and a GAP domain that inactivates Cdc42 (Wong and others 2001) .
Conclusions
The Rho family GTPases regulate the actin cytoskeleton and play a multitude of roles in CNS development and function. A principal effector of RhoA activity is the ROCK enzyme, and potent inhibitors of this kinase exist. A wide variety of cell surface signaling systems impinge on the Rho/ROCK pathway. Further analysis of these pathways is likely to accelerate molecular understanding in neuroscience and provide the potential for novel therapeutics in neurology.
